Results 121 to 130 of about 1,763,176 (361)

Protease inhibitors targeting coronavirus and filovirus entry. [PDF]

, 2015
In order to gain entry into cells, diverse viruses, including Ebola virus, SARS-coronavirus and the emerging MERS-coronavirus, depend on activation of their envelope glycoproteins by host cell proteases.
Agudelo, Juliet, Barnard, Dale, Carrion, Ricardo, Lu, Kai, McKerrow, James H, Nunneley, Jerritt W, Pöhlmann, Stefan, Renslo, Adam R, Simmons, Graham, Vedantham, Punitha, Zhou, Yanchen   +10 more
core   +1 more source

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates

Journal of Infectious Diseases, 2018
Background For most classes of drugs, rapid development of therapeutics to treat emerging infections is challenged by the timelines needed to identify compounds with the desired efficacy, safety, and pharmacokinetic profiles.
Kristen E. Pascal, Drew Dudgeon, John C. Trefry, Manu Anantpadma, Yasuteru Sakurai, C. D. Murin, H. Turner, J. Fairhurst, Marcela Torres, A. Rafique, Ying Yan, A. Badithe, Kevin Yu, Terra Potocky, S. Bixler, Taylor B. Chance, W. Pratt, Franco D. Rossi, J. Shamblin, S. Wollen, Justine M. Zelko, R. Carrion, Gabriella Worwa, Hilary M Staples, D. Burakov, R. Babb, Gang Chen, Joel Martin, Tammy Huang, Karl J. Erlandson, Melissa S Willis, Kimberly L. Armstrong, T. Dreier, A. Ward, R. Davey, M. Pitt, L. Lipsich, P. Mason, W. Olson, N. Stahl, C. Kyratsous   +40 more
semanticscholar   +1 more source

Cutaneous manifestations of the ebola virus [PDF]

Dermatology Online Journal, 2015
The current Ebola outbreak has drawn attention to the virus in the medical community. Zaire ebolavirus, more commonly known as 'the Ebola virus,' is a level 4-security agent in the Filoviridae family. The main cutaneous finding of Ebola is a nonspecific maculopapular rash that appears between day four and six of disease.
Blattner, Collin M, Mortazie, Michael B., Murase, Jenny E   +2 more
openaire   +5 more sources

Corporate governance and the early disclosure of systematic risk

Canadian Journal of Administrative Sciences / Revue Canadienne des Sciences de l'Administration, EarlyView.
Abstract Motivated by the need to understand firm characteristics associated with the disclosure of unexpected and unusual systematic risks, caused by events over which managers have little control, we examine the association between corporate governance and the early disclosure of such risks.
Abiodun S. Isiaka, Chima Mbagwu
wiley   +1 more source

Knowledge and attitude towards Ebola and Marburg virus diseases in Uganda using quantitative and participatory epidemiology techniques.

PLoS Neglected Tropical Diseases, 2017
BackgroundUganda has reported five (5) Ebola virus disease outbreaks and three (3) Marburg virus disease outbreaks from 2000 to 2016. Peoples' knowledge and attitude towards Ebola and Marburg virus disease impact on control and prevention measures ...
Luke Nyakarahuka, Eystein Skjerve, Daisy Nabadda, Doreen Chilolo Sitali, Chisoni Mumba, Frank N Mwiine, Julius J Lutwama, Stephen Balinandi, Trevor Shoemaker, Clovice Kankya   +9 more
doaj   +1 more source

Interferon-γ Inhibits Ebola Virus Infection. [PDF]

PLoS Pathogens, 2015
Ebola virus outbreaks, such as the 2014 Makona epidemic in West Africa, are episodic and deadly. Filovirus antivirals are currently not clinically available.
Bethany A Rhein, Linda S Powers, Kai Rogers, Manu Anantpadma, Brajesh K Singh, Yasuteru Sakurai, Thomas Bair, Catherine Miller-Hunt, Patrick Sinn, Robert A Davey, Martha M Monick, Wendy Maury   +11 more
doaj   +1 more source

Effect of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Vaccination on Ebola Virus Disease Illness and Death, Democratic Republic of the Congo

Emerging Infectious Diseases, 2022
We conducted a retrospective cohort study to assess the effect vaccination with the live-attenuated recombinant vesicular stomatitis virus–Zaire Ebola virus vaccine had on deaths among patients who had laboratory-confirmed Ebola virus disease (EVD).
Neil Rupani, Mbong Eta Ngole, J. Austin Lee, Adam R. Aluisio, Monique Gainey, Shiromi M. Perera, Lina Kashibura Ntamwinja, Ruffin Mbusa Matafali, Rigo Fraterne Muhayangabo, Fiston Nganga Makoyi, Razia Laghari, Adam C. Levine, Alexis S. Kearney   +12 more
doaj   +1 more source

Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies [PDF]

, 2006
Recombinant baculoviruses (rBV) expressing Ebola virus VP40 (rBV-VP40) or GP (rBV-GP) proteins were generated. Infection of Sf9 insect cells by rBV-VP40 led to assembly and budding of filamentous particles from the cell surface as shown by electron ...
Bennouna, Soumaya, Bu, Zhigao, Compans, Richard W., Lin, Jianguo, Lo, Michael, Pulendran, Bali, Sun, Yuliang, Wu, Qingyang, Yang, Chinglai, Ye, Ling   +9 more
core   +1 more source

Calcium ions directly interact with the Ebola virus fusion peptide to promote structure-function changes that enhance infection.

ACS Infectious Diseases, 2019
Ebola virus disease is a serious global health concern given its periodic occurrence, high lethality, and the lack of approved therapeutics. Certain drugs that alter intracellular calcium, particularly in endo-lysosomes, have been shown to inhibit Ebola ...
Lakshmi Nathan, A. Lai, J. Millet, Marco R. Straus, J. Freed, G. Whittaker, S. Daniel   +6 more
semanticscholar   +1 more source

Vaccines against Ebola virus [PDF]

Vaccine, 2018
We have just witnessed the largest and most devastating outbreak of Ebola virus disease, which highlighted the urgent need for development of an efficacious vaccine that could be used to curtail future outbreaks. Prior to 2014, there had been limited impetus worldwide to develop a vaccine since the virus was first discovered in 1976.
Venkatraman, N, Silman, D, Folegatti, P, Hill, A   +3 more
openaire   +4 more sources